Modality
Bispecific Ab
MOA
BiTE
Target
SHP2
Pathway
mTOR
NSCLCEpilepsy
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
~Oct 2023
→ ~Jan 2025
Phase 2
Apr 2025
→ Oct 2029
Phase 2Current
NCT08280922
1,083 pts·Epilepsy
2025-04→2029-10·Active
1,083 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-284w awayConference· Epilepsy
2029-10-033.5y awayPh3 Readout· Epilepsy
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Active
Catalysts
Conference
2026-04-28 · 4w away
Epilepsy
Ph3 Readout
2029-10-03 · 3.5y away
Epilepsy
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08280922 | Phase 2/3 | Epilepsy | Active | 1083 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |